Biotech Values

[mcbio]

A few weeks ago, a competitor was bought out by Baxter. Research firm Piper Jaffray said the Baxter acquisition has a positive read-through for Uniqure. The deal validates other hemophilia gene therapy programs in development, most notably Uniqure's, according to the firm. Analyst Joshua Schimmer wrote that there are other gene therapy programs for hemophilia in development beside Uniqure's and Baxter's, but he believes Uniqure has an advantage since it will be important to be among the first to market. The analyst also said that the market is large enough to accommodate more than one gene therapy option. Piper reiterated its Overweight rating and $35 price target on Uniqure.

If uniQure may have an advantage over the competitor that Baxter bought, then why didn't Baxter buy uniQure itself, rather than its competitor?